1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A

2.56
USD
-0.04
(-1.54%)
5.04BMarket Cap
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A
SGX:T14
(Singapore Exchange)

Recent

price

2.56

P/E

ratio

- -

div

yld

10.45%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2
2.47
2.94
3.46
4.01
3.97
3.42
3.12
3.48
3.82
3.62
3.79
4.52
4.5
4.01
2.69
- -
Revenue per Share
0.17
0.14
0.25
0.2
0.2
0.25
0.23
0.26
0.31
0.34
0.36
0.42
0.47
0.54
1.22
1.17
- -
Basic EPS, GAAP
0.04
0.07
-0.01
0.08
0.12
0.15
0.16
-0.07
0.1
0.16
0.26
0.38
0.31
0.3
0.44
0.19
- -
Free Cash Flow per Basic Share
0.02
0.11
0.08
0.09
0.07
0.08
0.11
0.07
0.09
0.09
0.13
0.13
0.21
0.48
0.55
0.54
1.81
Dividend per Share
1.03
1.07
1.22
1.38
1.58
2.15
2.29
2.48
2.7
2.95
3.17
3.47
3.55
3.61
4.29
3.89
3.25
Book Value per Share
0.91
0.96
1.12
1.27
1.47
2.05
2.19
2.38
2.61
2.86
3.05
3.36
3.35
3.4
4.1
3.72
3.09
Tangible Book Value per Share
1,739
1,780
1,744
1,738
1,768
1,785
1,827
1,821
1,825
1,832
1,825
1,824
1,825
1,828
1,823
1,825
1,034
Basic Weighted Avg Shares
3,473
4,392
5,130
6,010
7,087
7,081
6,243
5,689
6,359
6,994
6,604
6,908
8,249
8,222
7,307
4,917
- -
Sales/Revenue/Turnover
6.98
6.72
5.68
5.65
5.46
6.1
5.07
6.28
7.49
8.09
9.02
8.88
8.77
10.56
11.7
19.75
- -
Operating Margin (%)
96
97
94
83
84
70
70
73
76
98
111
116
117
130
126
116
- -
Depreciation Expense
293
248
441
352
358
451
424
476
562
626
662
769
862
987
2,229
2,131
- -
Net Income, GAAP
9.05
5.34
11.43
13.54
11.94
14.76
12.36
10.87
11.37
14.5
11.51
9.85
10.91
11.56
14.1
15.14
- -
Effective Tax Rate (%)
8.44
5.64
8.6
5.85
5.05
6.38
6.79
8.37
8.83
8.94
10.02
11.13
10.45
12
30.51
43.34
- -
Profit Margin (%)
234
289
415
635
1,020
2,158
1,985
2,108
2,865
2,978
3,440
3,991
3,912
3,319
3,790
2,648
1,718
Working Capital
144
1
4
4
4
4
4
39
4
33
32
2
152
244
6
5
5
LT Debt
2,087
2,205
2,279
2,575
2,947
4,105
4,345
4,666
5,054
5,523
5,950
6,514
6,552
6,645
7,850
7,100
5,940
Total Equity
10.62
9.18
14.92
10.63
10.18
10.57
8.51
9.96
11.23
12.03
12.18
12.67
13.13
14.05
29.25
27.63
- -
Return on Invested Capital (%)
11
9.3
15.13
11.42
10.26
11.44
9.87
10.13
11.01
11.41
11.16
12.04
12.87
15.04
30.67
28.7
- -
Return on Capital (%)
17.67
13.45
21.96
15.45
13.81
13.51
10.45
10.94
11.89
12.13
11.82
12.64
13.38
15.04
30.87
28.52
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
61
52
84
LT Borrowings
- -
- -
- -
LT Finance Leases
5
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,827
1,827
1,827
Market Capitalization
43,554
40,694
34,203

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,155
6,116
6,229
Cash, Cash Equivalents & STI
1,016
902
2,448
Accounts Receivable, Net
973
1,279
776
Inventories
1,133
1,078
1,111
Total Current Liabilities
4,506
2,829
4,510
Payables & Accruals
- -
- -
- -
ST Debt
61
52
84
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.86%
4.01%
-9.55%
Free Cash Flow
-23.03%
2.41%
-57.56%
Net Income, GAAP
20.57%
32.86%
-4.41%
Sales/Revenue/Turnover
-2.47%
-4.03%
-32.7%
Total Cash Common Dividend
27.89%
41.09%
-2.9%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,086
1,879
1,646
1,696
7,307
2025
1,455
1,195
- -
1,247
4,917
2026
1,515
939
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.35
0.19
1.85
1.22
2025
0.21
2.02
- -
-0.03
1.17
2026
0.23
0.29
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
1.26
0.04
0.55
2025
- -
- -
- -
- -
0.54
2026
1.03
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS), controlled by Tianjin Pharmaceutical Holdings Co., Ltd., manufactures and sells traditional Chinese medicines, western medicines, and healthcare products primarily in China with expanding international presence in Asia, Europe, and the United States; core offerings span 22 dosage forms and 599 drug approvals, including proprietary brands such as Suxiao Jiuxin Pills (national confidential dripping pills for cardiovascular conditions), Jingwanhong Ointment (national secret ointment for skin wound repair), Yinqiao Jiedu Tablets, Huoxiang Zhengqi Tincture, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, quick-acting heart saving pills under the China Heart series, Beijing Wanhong Ointment under the China Skin series, and China Brain series products; additional segments cover chemical raw materials, preparations, nutritional health products, drug retail, respiratory drugs, digestion drugs, and rheumatism treatments. Founded with roots tracing to 1669 and formally established in 1981, the company, headquartered at 17 Baidi Road, Nankai District, Tianjin, China, operates as a national high-tech enterprise pioneering modern TCM preparation technology, including the first GMP-certified TCM factory, and holds four China Time-Honored Brands (Da Ren Tang, Le Ren Tang, Ching Wan Hung, Long Shun Rong), five national intangible cultural heritage projects, and six well-known trademarks. In May 2022, the company renamed from Tianjin Zhongxin Pharmaceutical Group Corporation Limited to its current name, aligning with the 14th Five-Year Plan's "1+5" strategy focused on three core areas—cardiovascular and cerebrovascular drugs, skin wound repair drugs, high-quality TCM healthcare—and nine supporting lines; it renewed connected transaction agreements with Tianjin Pharmaceutical Group in November 2024 for chemical drugs and products effective January 2025; and in April 2025, agreed to sell its remaining 12% stake in Tianjin TSKF Pharmaceutical Co. Ltd joint venture to Haleon plc for CNY 1.62 billion, completing Haleon's full ownership.